Healthfirst does not cover Zepbound for weight loss across most of its New York plans. Coverage turns on which Healthfirst product you carry and why the drug was prescribed: a Medicaid, Essential Plan, or Medicare Advantage member seeking Zepbound purely for weight management will almost always be denied, while a member with a separate qualifying diagnosis, such as obstructive sleep apnea, may have a path to coverage. No New York law currently forces insurers to pay for anti-obesity medications, and federal Medicare rules bar Part D from covering weight-loss drugs at all.1HealthInsurance.org. Does Health Insurance Cover Drugs Used for Weight Loss2KFF. What Medicare’s Temporary Program Covering GLP-1s for Obesity Means for Beneficiaries
Zepbound, the brand name for tirzepatide, is FDA-approved for two uses: chronic weight management in adults with obesity or overweight plus a weight-related condition, and moderate to severe obstructive sleep apnea in adults with obesity.3FDA. Zepbound Prescribing Information That split matters, because insurers treat the two indications very differently.
Coverage by Healthfirst Plan Type
Medicaid Managed Care
Healthfirst Medicaid members get their outpatient drug benefit through NYRx, the statewide Medicaid pharmacy program that took over from managed care plans in April 2023.4Healthfirst. Formularies NYRx will not pay for GLP-1 drugs prescribed for weight loss. A NYRx bulletin states plainly that “weight loss is not and never has been a Medicaid-covered indication” under state regulations. GLP-1s are covered only for Medicaid-recognized indications like type 2 diabetes, subject to clinical criteria, and NYRx will not cover two GLP-1 agonists at once.5New York State Medicaid. NYRx GLP-1 Agonist Coverage Notification
Sleep apnea is the more nuanced case. Federal Medicaid rules require states to cover FDA-approved drugs for medically accepted indications, and KFF describes coverage of Zepbound’s OSA indication as required for Medicaid.6KFF. Medicaid Coverage of and Spending on GLP-1s New York has not been specifically identified as having activated an OSA-only coverage pathway for Zepbound within its Medicaid program, so a member with diagnosed moderate to severe OSA should confirm directly with NYRx or Healthfirst before assuming coverage.7FindHonestCare. Zepbound Medicaid Coverage
Essential Plan
The Essential Plan, New York’s subsidized coverage for people who earn too much for Medicaid, appears to exclude anti-obesity drugs from its pharmacy benefit. A UnitedHealthcare Community Plan preferred drug list for the Essential Plan lists “anti-obesity agents” among the plan’s exclusions.8UnitedHealthcare Community Plan. NY Preferred Drug List – Essential Plan The Essential Plan benefit package is standardized by the state, so Healthfirst Essential Plan members likely face the same exclusion. Check the Healthfirst formulary to confirm.4Healthfirst. Formularies
Leaf and Leaf Premier Marketplace Plans
Healthfirst’s commercial marketplace plans, Leaf and Leaf Premier, are Qualified Health Plans sold through the New York State of Health exchange.9Healthfirst Providers. Plans and Benefits For 2026, these plans share a formulary with the Essential Plan.10Healthfirst. Leaf Plans Commercial plans have more discretion than government-funded plans to cover anti-obesity medications, but with no state mandate they are not required to. The plan documents note that coverage has exclusions and limitations, and the publicly available material does not confirm whether tirzepatide for weight management is on the formulary. Search the 2026 Leaf/Essential formulary on the Healthfirst site or call the plan.
Medicare Advantage
Federal law prohibits Medicare Part D from covering drugs prescribed for weight loss.2KFF. What Medicare’s Temporary Program Covering GLP-1s for Obesity Means for Beneficiaries Every Healthfirst Medicare Advantage product, including the 65 Plus Plan, CompleteCare, Connection Plan, Increased Benefits Plan, Life Improvement Plan, and Signature HMO and PPO, is bound by that rule.4Healthfirst. Formularies If Zepbound is prescribed for a covered clinical indication like obstructive sleep apnea, the claim runs through the member’s Part D plan under normal formulary and utilization management rules.11CMS. Medicare GLP-1 Bridge Whether a specific Healthfirst Medicare plan lists tirzepatide for OSA requires checking that plan’s own formulary.
The Medicare GLP-1 Bridge for Weight Loss
Medicare members have a separate path for weight-loss use. Starting July 1, 2026, the federal government launched the Medicare GLP-1 Bridge, a temporary demonstration that covers Zepbound KwikPen for weight management at a $50 monthly copay.12CMS. CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries The program runs through December 31, 2027.13Medicare Rights Center. GLP-1 Weight Loss Drug Demonstration Begins July 2026
The Bridge operates outside Part D. Healthfirst Medicare Advantage plans do not process these claims, and providers submit prior authorization to a central CMS processor.11CMS. Medicare GLP-1 Bridge Bridge costs do not count toward Part D deductibles or out-of-pocket limits. You must be enrolled in a Part D plan to qualify, but your plan makes no coverage decision.2KFF. What Medicare’s Temporary Program Covering GLP-1s for Obesity Means for Beneficiaries A planned 2027 successor called BALANCE, which would have let Part D sponsors voluntarily cover weight-loss GLP-1s, has been delayed indefinitely.13Medicare Rights Center. GLP-1 Weight Loss Drug Demonstration Begins July 2026
What To Do if Healthfirst Denies Zepbound
Start by asking why. A denial may reflect a formulary exclusion, a missing prior authorization, or a blanket plan exclusion for anti-obesity agents, and each reason calls for a different response.
- Ask the prescriber to submit a prior authorization with a letter of medical necessity. Eli Lilly publishes a template that a physician can adapt and submit with supporting clinical documentation. If a non-weight-loss indication like obstructive sleep apnea applies, documenting it strengthens the case.14Eli Lilly. Zepbound Access and Coverage
- File an internal appeal with Healthfirst. New York law requires plans to offer internal review before an external appeal.15NY Department of Health. External Appeals
- File an external appeal with the New York Department of Financial Services if the internal appeal fails. You have four months from the plan’s final adverse determination to apply. Plans may charge a $25 fee per appeal, capped at $75 per year, waived for Medicaid and Child Health Plus members or in cases of financial hardship. Expedited reviews for non-formulary drugs are decided within 24 hours, and the external agent’s decision binds both the member and the plan.16NY DFS. File an External Appeal
External appeals involving tirzepatide have been won before. In a 2023 decision, a DFS external reviewer overturned an Aetna denial of Mounjaro (same active ingredient as Zepbound) for a patient with obesity who had not responded to another GLP-1, finding tirzepatide’s dual GLP-1 and GIP mechanism made it medically appropriate.17NY DFS. External Appeal Decision 202304-161488 That case involved a different insurer and a different brand, but the reasoning could inform a similar Healthfirst appeal.
Paying Out of Pocket
If Healthfirst will not cover Zepbound, manufacturer programs are the fallback. Eli Lilly’s LillyDirect self-pay pharmacy prices monthly Zepbound from $299 for the 2.5 mg dose to $449 for the 7.5 mg through 15 mg doses, provided refills are picked up within 45 days. Missing that window raises the top-dose price to $699 per month. These self-pay prices are not available to Medicare, Medicaid, or TRICARE members.18Eli Lilly. Zepbound Savings
Commercial members with Zepbound coverage may use a separate savings card that reduces copays to as low as $25 per fill, capped at $1,300 in annual savings. Commercial members without coverage can use the same card for up to $620 off per month, bringing costs to roughly $499.18Eli Lilly. Zepbound Savings Retail price without any discount runs about $1,270 per month.19GoodRx. Zepbound Price and Coupons All current manufacturer programs expire on December 31, 2026.
Pending New York Legislation
Several bills introduced in the 2025–2026 New York session would rewrite this picture if enacted. Senate Bill S3104 would require state-sponsored and commercial health plans to cover FDA-approved anti-obesity medications, with coverage criteria no more restrictive than the drugs’ FDA-approved indications, taking effect 180 days after signing.20New York State Senate. Senate Bill S3104 Assembly Bill A09360 would require Medicaid to cover FDA-approved GLP-1 receptor agonists for obesity, metabolic disorders, and autism-related compulsive eating behaviors.21BillTrack50. NY A09360 As of mid-2026, none have advanced beyond committee: S3104 sits in Senate Health, A04211 in Assembly Insurance, and A09360 was referred to Assembly Health in January 2026.22BillTrack50. NY A04211 Until one passes, Healthfirst and other New York insurers have no state-level obligation to cover anti-obesity drugs.